Abstract
Oncolytic viruses are attractive therapeutics for cancer because they selectively amplify, through replication and spread, the input dose of virus in the target tumor. To date, clinical trials have demonstrated marked safety but have not realized their theoretical efficacy potential. In this review, we consider the potential of armed therapeutic viruses, whose lytic potential is enhanced by genetically engineered therapeutic transgene expression from the virus, as potential vehicles to increase the potency of these agents. Several classes of therapeutic genes are outlined, and potential synergies and hurdles to their delivery from replicating viruses are discussed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Wildner O . Oncolytic viruses as therapeutic agents Ann Med 2001 33: 291–304
Ring CJ . Cytolytic viruses as potential anti-cancer agents J Gen Virol 2002 83: Pt 3 491–502
Kirn D . Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer Oncogene 2000 19: 6660–6669
Hermiston T . Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer J Clin Invest 2000 105: 1169–1172
Khuri FR, Nemunaitis J, Ganly I et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nat Med 2000 6: 879–885
Smith RR, Huebner RJ, Rowe WP, Schatten WE, Thomas LB . Studies on the use of viruses in the treatment of carcinoma of the cervix Cancer 1956 9: 1211–1218
Kirn D . Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer Oncogene 2000 19: 6660–6669
Reid T, Galanis E, Abbruzzese J et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial Gene Ther 2001 8: 1618–1626
Nemunaitis J, Khuri F, Ganly I et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer J Clin Oncol 2001 19: 289–298
Markert JM, Medlock MD, Rabkin SD et al. Conditionally replicating herpes simplex virus mutant, G207, for the treatment of malignant glioma: results of a phase I trial Gene Ther 2000 7: 867–874
Rampling R, Cruickshank G, Papanastassiou V et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma Gene Ther 2000 7: 859–866
Pecora AL, Rizvi N, Cohen GI et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers J Clin Oncol 2002 20: 2251–2266
Csatary LK, Moss RW, Beuth J et al. Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H) Anticancer Res 1999 19: 635–638
Csatary LK, Bakacs T . Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma JAMA 1999 281: 1588–1589
Kirn D, Niculesco-Duvaz I, Halden G, Springer CJ . The emerging fields of suicide gene therapy and virotherapy Trends Mol Med 2002 8: S68–S73
Hermiston T . Fighting fire with fire: attacking the complexity of human tumors with armed therapeutic viruses Curr Opin Mol Ther 2002 4: 334–342
McCormick F . Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer 2001 1: 130–141
Wilson DR . Viral-mediated gene transfer for cancer treatment Curr Pharmacol Biotechnol 2002 3: 151–164
Willis AC, Chen X . The promise and obstacle of p53 as a cancer therapeutic agent Curr Mol Med 2002 2: 329–345
Levine A, DiMiao D, Coen DM . Fields Virology (Fourth Edition) 2001 1: 3–18 119–132
Nishizaki M, Fujiwara T, Tanida T et al. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect Clin Cancer Res 1999 5: 1015–1023
Buckbinder L, Talbott R, Velasco-Miguel S et al. Induction of the growth inhibitor IGF-binding protein 3 by p53 Nature 1995 377: 646–649
Mueller H . Tumor necrosis factor as an antineoplastic agent: pitfalls and promises Cell Mol Life Sci 1998 54: 1291–1298
Sauthoff H, Pipiya T, Heitner S et al. Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein Hum Gene Ther 2002 (In press)
Moolten FL . Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy Cancer Res 1986 46: 5276–5281
Stribbling SM, Friedlos F, Martin J et al. Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect Hum Gene Ther 2000 11: 285–292
Knox RJ . Gene-directed enzyme prodrug therapy (GDEPT) — recognizing the present limitations of gene therapy for the treatment of cancer Curr Opin Invest Drugs 2001 2: 835–838
Freytag SO, Kim JH, Khil MS et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for local recurrence of prostate cancer Proc Am Assoc Cancer Res 2002 43: (Abstract 5429)
Hawkins LK, Hermiston T . Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region Gene Ther 2001 8: 1142–1148
van Dillen IJ, Mulder NH, Vaalburg W, de Vries EF, Hospers GA . Influence of the bystander effect on HSV-tk/GCV gene therapy. A review Curr Gene Ther 2002 2: 307–322
Ichikawa T, Chiocca EA . Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or defective viral vector Cancer Res 2001 61: 5336–5339
Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH . A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy Hum Gene Ther 1998 9: 1323–1333
Wildner O, Morris JC . Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses J Gene Med 2000 2: 353–360
McCart JA, Puhlmann M, Lee J et al. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression Gene Ther 2000 7: 1217–1223
Ichikawa T, Petros WP, Ludeman SM et al. Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector Cancer Res 2001 61: 864–868
Lee YJ, Galoforo SS, Battle P et al. Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy Cancer Gene Ther 2001 8: 397–404
Nemunaitis J, Swisher SG, Timmons T et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer J Clin Oncol 2000 18: 609–622
Sanchez-Prieto R, Quintanilla M, Cano A et al. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene Oncogene 1996 13: 1083–1092
Toyoizumi T, Mick R, Abbas AE et al. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer Hum Gene Ther 1999 10: 3013–3029
You L, Yang CT, Jablons DM . ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients Cancer Res 2000 60: 1009–1013
Folkman J . Tumor angiogenesis Adv Cancer Res 1985 43: 175–203
Folkman J . What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990 82: 4–6
Thompson WD, Li WW, Maragoudakis M . The clinical manipulation of angiogenesis: pathology, side-effects, surprises, and opportunities with novel human therapies J Pathol 2000 190: 330–337
Folkman J . Therapeutic angiogenesis in ischemic limbs Circulation 1998 97: 1108–1110
Denekamp J . Vascular attack as a therapeutic strategy for cancer Cancer Metastasis Rev 1990 9: 267–282
St Croix B, Rago C, Velculescu V et al. Genes expressed in human tumor endothelium Science 2000 289: 1197–1202
Talks KL, Harris AL . Current status of antiangiogenic factors Br J Haematol 2000 109: 477–489
Feldman AL, Libutti SK . Progress in antiangiogenic gene therapy of cancer Cancer 2000 89: 1181–1194
Kleinman HK, Liau G . Gene therapy for antiangiogenesis J Natl Cancer Inst 2001 93: 965–967
Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D . Effects of angiogenesis inhibitors on multistage carcinogenesis in mice Science 1999 284: 808–812
Coussens LM, Fingleton B, Matrisian LM . Matrix metalloproteinase inhibitors and cancer: trials and tribulations Science 2002 295: 2387–2392
Lund EL, Bastholm L, Kristjansen PE . Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts Clin Cancer Res 2000 6: 971–978
Bello L, Carrabba G, Giussani C et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo Cancer Res 2001 61: 7501–7506
Hood JD, Bednarski M, Frausto R et al. Tumor regression by targeted gene delivery to the neovasculature Science 2002 296: 2404–2407
Savontaus MJ, Sauter BV, Huang TG, Woo SL . Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells Gene Ther 2002 9: 972–979
Steinman RM . The dendritic cell system and its role in immunogenicity Annu Rev Immunol 1991 9: 271–296
Steinman RM . Dendritic cells and immune-based therapies Exp Hematol 1996 24: 859–862
Steinman RM, Pack M, Inaba K . Dendritic cell development and maturation Adv Exp Med Biol 1997 417: 1–6
Lanzavecchia A . Identifying strategies for immune intervention Science 1993 260: 937–944
Banchereau J, Steinman RM . Dendritic cells and the control of immunity Nature 1998 392: 245–252
Dallal RM, Lotze MT . Immunotherapy of metastasis Surg Oncol Clin North Am 2001 10: 433–447, xi
Caux C, Massacrier C, Vanbervliet B et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte–macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis Blood 1997 90: 1458–1470
Young JW, Szabolcs P, Moore MA . Identification of dendritic cell colony-forming units among normal human CD34+ one marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha J Exp Med 1995 182: 1111–1119
Chinnaiyan AM, Hanna WL, Orth K et al. Cytotoxic T-cell–derived granzyme B activates the apoptotic protease ICE-LAP3 Curr Biol 1996 6: 897–899
Froelich CJ, Dixit VM, Yang X . Lymphocyte granule–mediated apoptosis: matters of viral mimicry and deadly proteases Immunol Today 1998 19: 30–36
Alderson MR, Tough TW, Davis-Smith T et al. Fas ligand mediates activation-induced cell death in human T lymphocytes J Exp Med 1995 181: 71–77
Lynch DH, Alderson MR, Ramsdell F . Immunoregulatory effects of Fas-mediated signalling J Cell Biochem 1996 60: 39–46
Dranoff G . Tumor immunology: immune recognition and tumor protection Curr Opin Immunol 2002 14: 161–164
Vicari AP, Caux C . Chemokines in cancer Cytokine Growth Factor Rev 2002 13: 143–154
Vicari AP, Caux C, Trinchieri G . Tumour escape from immune surveillance through dendritic cell inactivation Semin Cancer Biol 2002 12: 33–42
Hellstrom I, Hellstrom KE . Tumor immunology: an overview Ann NY Acad Sci 1993 690: 24–33
Hellstrom KE, Hellstrom I, Linsley P, Chen L . On the role of costimulation in tumor immunity Ann NY Acad Sci 1993 690: 225–230
Nakagomi H, Petersson M, Magnusson I et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma Cancer Res 1993 53: 5610–5612
Finke JH, Zea AH, Stanley J et al. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma Cancer Res 1993 53: 5613–5616
Ferrone S, Marincola FM . Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance Immunol Today 1995 16: 487–494
Seliger B, Maeurer MJ, Ferrone S . TAP off-tumors on Immunol Today 1997 18: 292–299
Hersey P . Impediments to successful immunotherapy Pharmacol Ther 1999 81: 111–119
Morford LA, Elliott LH, Carlson SL, Brooks WH, Roszman TL . T cell receptor–mediated signaling is defective in T cells obtained from patients with primary intracranial tumors J Immunol 1997 159: 4415–4425
Sogn JA . Tumor immunology: the glass is half full Immunity 1998 9: 757–763
Ling W, Rayman P, Uzzo R et al. Impaired activation of NFkappaB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IkappaBalpha Blood 1998 92: 1334–1341
Drake CG, Pardoll DM . Tumor immunology — towards a paradigm of reciprocal research Semin Cancer Biol 2002 12: 73–80
Pardoll DM . Spinning molecular immunology into successful immunotherapy Nat Rev Immunol 2002 2: 227–238
O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F . Resistance to Fas (APO-1/CD95)–mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack Dis Esophagus 1999 12: 83–89
Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 2002 8: 793–800
Gimmi CD, Morrison BW, Mainprice BA et al. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells Nat Med 1996 2: 1367–1370
Moss B . Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety Proc Natl Acad Sci USA 1996 93: 11341–11348
Andreansky S, He B, van Cott J et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins Gene Ther 1998 5: 121–130
Kurihara T, Brough DE, Kovesdi I, Kufe DW . Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen J Clin Invest 2000 106: 763–771
Wong RJ, Patel SG, Kim S et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma Hum Gene Ther 2001 12: 253–265
Bennett JJ, Malhotra S, Wong RJ et al. Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer Ann Surg 2001 233: 819–826
Hawkins LK, Johnson L, Bauzon M et al. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region Gene Ther 2001 8: 1123–1131
Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG . Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection Br J Cancer 2000 82: 1009–1012
Roizman B . The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors Proc Natl Acad Sci USA 1996 93: 11307–11312
Kiessling R, Wasserman S, Horiguchi S et al. Tumor-induced immune dysfunction Cancer Immunol Immunother 1999 48: 353–362
Li E, Stupack D, Bokuch GM, Nemerow GR . Adenovirus endocytosis requires actin cytoskeleton reorganization mediated by Rho family GTPases J Virol 1998 72: 8806–8812
Roymans D, Slegers H . Phosphatidylinositol 3-kinases in tumor progression Eur J Biochem 2001 268: 487–498
Hawkins LK, Hermiston TW . Gene delivery from the E3 region of replicating human adenovirus: evaluation of the ADP region Gene Ther 2001 8: 1132–1141
Nanda D, Vogels R, Havenga M et al. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase Cancer Res 2001 61: 8743–8750
Katso R, Okkenhaug K, Ahmadi K et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer Annu Rev Cell Dev Biol 2001 17: 615–675
Berrie CP . Phosphoinositide 3-kinase inhibition in cancer treatment Expert Opin Invest Drugs 2001 10: 1085–1098
Hawkins LK, Lemoine NR, Kirn D . Oncolytic biotherapy: a novel therapeutic platform Lancet Oncol 2002 3: 17–26
Kirn D, Martuza RL, Zwiebel J . Replication-selective virotherapy for cancer: biological principles, risk management and future directions Nat Med 2001 7: 781–787
Timiryasova TM, Li J, Chen B et al. Antitumor effect of vaccinia virus in glioma model Oncol Res 1999 11: 133–144
Coffey MC, Strong JE, Forsyth PA, Lee PW . Reovirus therapy of tumors with activated Ras pathway Science 1998 282: 1332–1334
Stojdl DF, Lichty B, Knowles S et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus Nat Med 2000 6: 821–825
Ganly I, Kirn D, Eckhardt G et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 2000 6: 798–806
Vasey PA, Shulman LN, Campos S et al. Phase I trial of intraperitoneal injection of the E1B–55-kd-gene–deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer J Clin Oncol 2002 20: 1562–1569
Bischoff JR, Kirn DH, Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Science 1996 274: 373–376
Mulvihill S, Warren R, Venook A et al. Safety and feasibility of injection with an E1B–55 kDa gene–deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial Gene Ther 2001 8: 308–315
Habib N, Salama H, Abd El Latif Abu Median A et al. Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma Cancer Gene Ther 2002 9: 254–259
Freytag SO, Khil M, Stricker H et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer Cancer Res 2002 62: 4968–4976
Wildner O, Blaese RM, Morris JC . Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase Cancer Res 1999 59: 410–413
Heise C, Hermiston T, Johnson L et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy Nat Med 2000 6: 1134–1139
Fueyo J, Gomez-Manzano C, Alemany R et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo Oncogene 2000 19: 2–12
Suzuki K, Fueyo J, Krasnykh V et al. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency Clin Cancer Res 2001 7: 120–126
Howe JA, Demers GW, Johnson DE et al. Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy Mol Ther 2000 2: 485–495
Doronin K, Toth K, Kuppuswamy M et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein J Virol 2000 74: 6147–6155
Doronin K, Kuppuswamy M, Toth K et al. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy J Virol 2001 75: 3314–3324
DeWeese TL, van der Poel H, Li S et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy Cancer Res 2001 61: 7464–7472
Chen Y, DeWeese T, Dilley J et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity Cancer Res 2001 61: 5453–5460
Yu DC, Chen Y, Dilley J et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel Cancer Res 2001 61: 517–525
Fuerer C, Iggo R . Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway Gene Ther 2002 9: 270–281
Johnson L, Shen A, Boyle L et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents Cancer Cell 2002 1: 325–337
Hallenbeck PL, Chang YN, Hay C et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma Hum Gene Ther 1999 10: 1721–1733
Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT . Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter Cancer Res 2002 62: 4663–4670
Ramachandra M, Rahman A, Zou A et al. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy Nat Biotechnol 2001 19: 1035–1041
Tsukuda K, Wiewrodt R, Molnar-Kimber K, Jovanovic VP, Amin KM . An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell Cancer Res 2002 62: 3438–3447
Takahashi M, Sato T, Sagawa T et al. E1B–55K–deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor Mol Ther 2002 5: 627–634 (Part 1)
Fabra A, Parada C, Vinyals A et al. Intravascular injections of a conditional replicative adenovirus (adl118) prevent metastatic disease in human breast carcinoma xenografts Gene Ther 2001 8: 1627–1634
Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL . Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas Nat Med 1995 1: 938–943
MacLean AR, ul-Fareed M, Robertson L, Harland J, Brown SM . Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the “a” sequence J Gen Virol 1991 72: 631–639
Delman KA, Bennett JJ, Zager JS et al. Effects of preexisting immunity on the response to herpes simplex–based oncolytic viral therapy Hum Gene Ther 2000 11: 2465–2472
Pyles RB, Warnick RE, Chalk CL, Szanti BE, Parysek LM . A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors Hum Gene Ther 1997 8: 533–544
Parker LP, Wolf JK, Price JE . Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines Ann Clin Lab Sci 2000 30: 395–405
Fu X, Zhang X . Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype Cancer Res 2002 62: 2306–2312
Chase M, Chung RY, Chiocca EA . An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy Nat Biotechnol 1998 16: 444–448
Pawlik TM, Nakamura H, Mullen JT et al. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene Cancer 2002 95: 1171–1181
Mineta T, Rabkin SD, Martuza RL . Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant Cancer Res 1994 54: 3963–3966
Boviatsis EJ, Park JS, Sena-Esteves M et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene Cancer Res 1994 54: 5745–5751
Todo T, Martuza RL, Rabkin SD, Johnson PA . Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing Proc Natl Acad Sci USA 2001 98: 6396–6401
Miyatake S, Iyer A, Martuza RL, Rabkin SD . Transcriptional targeting of herpes simplex virus for cell-specific replication J Virol 1997 71: 5124–5132
Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM . Experimental therapy of human glioma by means of a genetically engineered virus mutant Science 1991 252: 854–856
Chung RY, Saeki Y, Chiocca EA . B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells J Virol 1999 73: 7556–7564
Nakamura H, Mullen JT, Chandrasekhar S et al. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil Cancer Res 2001 61: 5447–5452
Markert JM, Malick A, Coen DM, Martuza RL . Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir Neurosurgery 1993 32: 597–603
Whitman ED, Tsung K, Paxson J, Norton JA . In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy Surgery 1994 116: 183–188
Puhlmann M, Gnant M, Brown CK, Alexander HR, Bartlett DL . Thymidine kinase–deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy Hum Gene Ther 1999 10: 649–657
Peplinski GR, Tsung K, Meko JB, Norton JA . Prevention of murine breast cancer by vaccination with tumor cells modified by cytokine-producing recombinant vaccinia viruses Ann Surg Oncol 1996 3: 15–23
Peplinski GR, Tsung K, Casey MJ et al. In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleukin-1beta Cancer J Sci Am 1996 2: 21
Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC et al. Intratumoral recombinant GM-CSF–encoding virus as gene therapy in patients with cutaneous melanoma Cancer Gene Ther 1999 6: 409–422
Gnant MF, Puhlmann M, Alexander HR Jr, Bartlett DL . Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice Cancer Res 1999 59: 3396–3403
Mukherjee S, Haenel T, Himbeck R et al. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation Cancer Gene Ther 2000 7: 663–670
Hodge JW, Sabzevari H, Yafal AG et al. A triad of costimulatory molecules synergize to amplify T-cell activation Cancer Res 1999 59: 5800–5807
McCart JA, Ward JM, Lee J et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes Cancer Res 2001 61: 8751–8757
Norman KL, Coffey MC, Hirasawa K et al. Reovirus oncolysis of human breast cancer Hum Gene Ther 2002 13: 641–652
Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E . Intergeneric poliovirus recombinants for the treatment of malignant glioma Proc Natl Acad Sci USA 2000 97: 6803–6808
Balachandran S, Porosnicu M, Barber GN . Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis J Virol 2001 75: 3474–3749
Peng KW, TenEcyck CJ, Galanis E et al. Intraperitoneal therapy of ovarian cancer using an engineered measles virus Cancer Res 2002 62: 4656–4662
Peng KW, Ahmann GJ, Pham L et al. Systemic therapy of myeloma xenografts by an attenuated measles virus Blood 2001 98: 2002–2007
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hermiston, T., Kuhn, I. Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther 9, 1022–1035 (2002). https://doi.org/10.1038/sj.cgt.7700542
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700542
Keywords
This article is cited by
-
Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis
Scientific Reports (2020)
-
A tumor targeting oncolytic adenovirus can improve therapeutic outcomes in chemotherapy resistant metastatic human breast carcinoma
Scientific Reports (2019)
-
Sindbis Viral Vectors Transiently Deliver Tumor-associated Antigens to Lymph Nodes and Elicit Diversified Antitumor CD8+ T-cell Immunity
Molecular Therapy (2014)
-
Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers
Cancer Gene Therapy (2013)
-
Adenoviral gene therapy in hepatocellular carcinoma: a review
Hepatology International (2013)